|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
This preliminary study identifies MBL and ficolin-2 as potential biomarkers for the development of HCC in chronic HCV infection.
|
30798068 |
2019 |
|
Hepatitis C
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Interestingly, C9 is significantly reduced at the mRNA level in chronically HCV infected liver biopsy specimens, while many hepatocyte derived complement components (C6, C8, Factor B, MASP1, and MBL) and unrelated genes remain mostly unaffected.
|
30593637 |
2019 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results provide new insights to understand the MBL molecular forms profile in patients infected with HCV- which could be useful in future investigations on the influence of the MBL structure/genotype on both the progression of infection and the response to hepatitis C therapy.
|
30056939 |
2018 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
MBL-HCV1, a neutralizing human monoclonal antibody (mAb) targeting the HCV envelope, was combined with a licensed oral direct-acting antiviral (DAA) to prevent HCV recurrence post-transplant in an open-label exploratory efficacy trial.
|
28127942 |
2017 |
|
Hepatitis C
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Moreover, a meta-analysis to assess the role of MBL2 polymorphisms in HCV infection susceptibility was also performed: YA haplotype could be associated with protection towards HCV infection.
|
27136459 |
2016 |
|
Hepatitis C
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Serum MBL levels from 50 CHC patients who completed treatment at least 24 weeks before the present study and 75 healthy HCV-negative controls were measured.
|
25599785 |
2014 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
The ability of MBL-HCV1 to prevent HCV recurrence after liver transplantation was investigated in a phase 2 randomized clinical trial evaluating six MBL-HCV1-treated subjects and five placebo-treated subjects.
|
24956119 |
2014 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
Mannan binding lectin-associated serine protease 1 is induced by hepatitis C virus infection and activates human hepatic stellate cells.
|
23841802 |
2013 |
|
Hepatitis C
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
MBL-2 polymorphisms and gender are involved in the development of ACR after LT. CC genotype and gender match may be regarded as risk factors for ACR in HCV-positive graft recipients.
|
22650645 |
2012 |
|
Hepatitis C
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The aim of our study was to determine the prevalence of MBL-2 polymorphism (rs7096206) in hepatitis C virus (HCV)-induced hepatocellular carcinoma (HCC) based on histological analysis of explanted livers in patients undergoing liver transplantation (LT).
|
21733090 |
2011 |
|
Hepatitis C
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We conclude that MBL variant alleles expressing low levels of MBL are associated with the susceptibility to HCV infection and that the inheritance of HYO haplotype could be associated with fibrosis severity.
|
20570631 |
2010 |
|
Hepatitis C
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The odds ratio estimations were not significant, and the values obtained cannot suggest that the presence of allele variant MBL*B could have some influence in the risk of HCV infection progression to liver cirrhosis and that the presence of allele MBL*D could confer some protection against disease progression, but a larger sample size is necessary to confirm the present results.
|
19540295 |
2009 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
MBL may play a role as disease modifier in HCV infection.
|
19703233 |
2009 |
|
Hepatitis C
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We examined whether MBL2 variants influence the outcome of hepatitis C virus (HCV) infection.
|
18452612 |
2008 |
|
Hepatitis C
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Response to antiviral treatment was related to hepatitis C virus genotype (p < 0.001, OR = 10.9), but not to MBL2 genotype or serum MBL levels.
|
18592362 |
2008 |
|
Hepatitis C
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our data do not seem to suggest a role for MBL2 and MASP2 polymorphisms in HCC susceptibility either for HBV-HCV infection-dependent HCC or for HCC raised as a consequence of exposure to different risk factors.
|
18221301 |
2008 |
|
Hepatitis C
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Here we summarise the effect of MBL2 polymorphisms on MBL function and how this may relate to disease outcome in HBV and HCV infection.
|
17157924 |
2007 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our findings indicate that MBL might represent an important antiviral molecule having a protective role in the first stages of HCV infection, as shown by the increased frequency of wild-type alleles in control population as compared to the infected group.
|
17513174 |
2007 |
|
Hepatitis C
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To determine whether MBL gene polymorphisms affect the course of HCV infection, we investigated the association between MBL gene polymorphisms and HCV infection in Japanese subjects.
|
11063157 |
2000 |
|
Hepatitis C
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We aimed to find any relevance of mannose-binding lectin polymorphism to hepatitis C virus infection.
|
9833905 |
1998 |